A recent study found further evidence that hepatitis C reinfection rates are greater in drug users despite successful treatment with direct-acting antiviral therapy.
People who inject drugs (PWIDs) are more likely to experience hepatitis C virus (HCV) reinfection, even after being successfully treated with direct-acting antiviral (DAA) therapy, according to a population-based study of 1.7 million-plus individuals tested for HCV.
The findings from the research team at the British Columbia Center for Disease Control and the University of British Columbia (UBC), presented at the
in San Francisco, CA, also suggest that opiate agonist therapy (OAT) could be a viable combatant for reinfection rates.
Led by Carmine Rossi, PhD, of UBC, investigators analyzed the clinical outcomes of HCV patients in Canada treated with DAAs between January 2014 and July 2017. Qualified patients had achieved sustained virologic response (SVR) and had been subjected to at least 1 subsequent HCV RNA test for reinfection. They defined reinfection as a single positive RNA test after reaching SVR.
Persistent reinfections were defined when individuals did not spontaneously clear. Investigators also assessed for both current PWIDs—<3 years before SVR—and former PWIDs—≥3 years before SVR—using an algorithm dependent on physician diagnoses and hospitalization codes. They then calculated crude reinfection rates per 100 person-years (PYs), and modeled age- and sex-adjusted incidence rate ratios (IRRs) using Poisson regression.
Among the approximate 1.7 million initially assessed, 4114 met cohort inclusion. A majority of patients were found to be male (65%), born prior to 1965 (83%), and to have had a history of injection drug use—either as a current (21%) or former (44%) PWID.
Just 40 reinfections (33 persistent) were found over 2767 PYs, indicating a reinfection rate of 1.45 per 100 PYs. Among current PWID, crude reinfection rates were 3.1 per 100 PYs (IRR: 8.0; 95% CI: 2.4-27). Among former PWID, rates were 1.4 per 100 PYs (IRR: 4.2; 95% CI: 1.2-14), while non-PWID reported rates of just 0.3 per 100 PYs.
Continue reading on MD Magazine.